Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $6.50 Average Target Price from Analysts

Posted by on Jun 17th, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.50.

MYGN has been the topic of a number of recent analyst reports. UBS Group lowered their price target on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. Zacks Research raised Myriad Genetics from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Weiss Ratings raised Myriad Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. TD Cowen lowered their price target on Myriad Genetics from $7.00 to $6.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company lowered their price target on Myriad Genetics from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th.

Check Out Our Latest Stock Report on Myriad Genetics

Insider Buying and Selling

In other Myriad Genetics news, Director Rashmi Kumar sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $4.46, for a total transaction of $66,900.00. Following the transaction, the director owned 171,889 shares of the company’s stock, valued at $766,624.94. The trade was a 8.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Paul Bisaro purchased 7,500 shares of the stock in a transaction on Thursday, May 14th. The shares were acquired at an average cost of $3.69 per share, for a total transaction of $27,675.00. Following the transaction, the director owned 97,441 shares of the company’s stock, valued at approximately $359,557.29. The trade was a 8.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Amundi grew its position in shares of Myriad Genetics by 79.2% in the first quarter. Amundi now owns 27,976 shares of the company’s stock valued at $126,000 after purchasing an additional 12,367 shares during the last quarter. Quantinno Capital Management LP grew its position in shares of Myriad Genetics by 26.8% in the first quarter. Quantinno Capital Management LP now owns 90,622 shares of the company’s stock valued at $408,000 after purchasing an additional 19,179 shares during the last quarter. Orbimed Advisors LLC acquired a new position in shares of Myriad Genetics in the first quarter valued at approximately $562,500,000. Weiss Asset Management LP acquired a new position in shares of Myriad Genetics in the first quarter valued at approximately $787,000. Finally, Renaissance Technologies LLC grew its position in shares of Myriad Genetics by 19.8% in the first quarter. Renaissance Technologies LLC now owns 454,374 shares of the company’s stock valued at $2,045,000 after purchasing an additional 75,000 shares during the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics Stock Down 1.6%

MYGN stock opened at $4.25 on Wednesday. The company has a quick ratio of 2.19, a current ratio of 2.40 and a debt-to-equity ratio of 0.36. The business has a 50 day moving average price of $4.40 and a two-hundred day moving average price of $5.22. The company has a market cap of $401.41 million, a price-to-earnings ratio of -0.99 and a beta of 1.73. Myriad Genetics has a twelve month low of $3.53 and a twelve month high of $8.59.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $200.40 million during the quarter, compared to the consensus estimate of $202.42 million. Myriad Genetics had a negative net margin of 48.24% and a negative return on equity of 8.51%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) earnings per share. Analysts anticipate that Myriad Genetics will post -0.17 EPS for the current fiscal year.

Myriad Genetics Company Profile

(Get Free Report)

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.

Featured Articles

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.